BridgeBio Pharma. has been granted a patent for methods to treat transthyretin (TTR) amyloidosis, specifically ATTR cardiomyopathy. The patent details a dosing regimen involving a total daily dosage of approximately 1,600 mg of Compound 1, demonstrating efficacy and tolerability in subjects. GlobalData’s report on BridgeBio Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on BridgeBio Pharma, was a key innovation area identified from patents. BridgeBio Pharma's grant share as of July 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment methods for transthyretin amyloidosis (attr) cardiomyopathy
The granted patent US12070449B2 outlines a method for treating transthyretin amyloidosis (ATTR) cardiomyopathy through the oral administration of a compound referred to as Compound 1, specifically in its HCl salt form or an equivalent formulation. The recommended total daily dosage is approximately 1,600 milligrams. The claims detail the potential benefits of this treatment, including improvements in physical performance as measured by the six-minute walk test, stabilization of walking distance, and a reduction in cardiovascular-related hospitalizations. The patent also distinguishes between wild-type and variant forms of ATTR cardiomyopathy, with specific mutations in the transthyretin (TTR) protein being highlighted for variant ATTR cardiomyopathy.
Additionally, the patent claims that the administration of Compound 1 may lead to a decrease in mortality rates among treated subjects, with reductions noted at various percentages after 30 months of treatment. The method is also associated with increased serum concentrations of TTR and decreased levels of N-terminal pro-brain natriuretic peptide (N-terminal pro-BNP), which is indicative of heart failure. Furthermore, improvements in the Kansas City Cardiomyopathy Questionnaire (KCCQ) classification are anticipated, suggesting enhanced quality of life for patients undergoing this treatment. Overall, the patent presents a comprehensive approach to managing ATTR cardiomyopathy, emphasizing both clinical outcomes and patient well-being.
To know more about GlobalData’s detailed insights on BridgeBio Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
